Blood and Blood Components Market, by Product Type (Whole Blood and Blood Components (Red Blood Cells, White Blood Cells, Platelets, and Plasma)), by Application (Anemia, Trauma and Surgery, Cancer Treatment, Bleeding Disorders, and Others (Others include

Blood and Blood Components Market, by Product Type (Whole Blood and Blood Components (Red Blood Cells, White Blood Cells, Platelets, and Plasma)), by Application (Anemia, Trauma and Surgery, Cancer Treatment, Bleeding Disorders, and Others (Others include rare blood diseases)), by End User (Hospitals, Ambulatory Surgical Centers, Blood and Blood Component Bank, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Blood is a specialized bodily fluid that circulates through the entire body with the help of a network of blood vessels such as arteries, veins, and capillaries. Blood is made up of four major components, which include red blood cells, white blood cells, plasma, and platelets. Red blood cells, also known as erythrocytes or RBC account for the major portion of blood cells. RBC have a specialized red colored pigment called hemoglobin, which is responsible for carrying oxygen rich blood from the lungs to the rest of the body and deoxygenated blood from the body to the lungs. The average life cycle of RBC is 120 days after which they are removed by the spleen. White blood cells, also known as leukocytes are responsible for making the immune system of the body and help fight against microbial infections. Plasma is the liquid component of blood and is a mixture of water, protein, sugar, salts, and fat. Platelets, also known as thrombocytes help in clotting of blood at the site of tissue injury. Whole blood consists of 45% blood cells and 55% plasma.
According to the American Society of Hematology, blood makes up around 7 to 8% of human body weight. Blood and blood components are used for blood transfusion in case of blood loss during a traumatic injury, hemorrhage to maintain blood volume during cancer treatment, and to treat bleeding disorders.
Market Dynamics
The increasing incidence of bleeding disorders and chronic diseases, rising research and development activities for the development of novel technology for the treatment of bleeding disorders, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global blood and blood components market over the forecast period.
For instance, according to the statistics provided by the World Federation of Hemophilia (WFH) in 2018, over 400,000 people suffered from hemophilia of which around 173,000 people were diagnosed with hemophilia A or B in 2017, across the globe.
Key features of the study:
This report provides in-depth analysis of the global blood and blood components market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global blood and blood components market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Becton, Dickinson & Co., Kidde-Fenwal Inc., Bio-Rad Laboratories, Inc., Cerus Corporation, Immucor, Beckman Coulter, Inc., bioMérieux SA, Octapharma AG, Abbott, CSL Behring LLC, MacoPharma, Shanghai RAAS, China Biologic Products Holdings, Inc., Takeda Pharmaceutical Company Limited, Grifols S.A., Bharat Serums and Vaccines Ltd., and Terumo BCT Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global blood and blood components market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood and blood components market
Detailed Segmentation:
Global Blood and Blood Components Market, By Product Type:
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
Global Blood and Blood Components Market, By Application:
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
Global Blood and Blood Components Market, By End User:
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
Global Blood and Blood Components Market, By Region:
North America
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country
U.S.
Canada
Latin America
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country
GCC
Israel
Rest of Middle East
Africa
By Product Type
Whole Blood
Blood Components
Red Blood Cells
White Blood Cells
Platelets
Plasma
By Application
Anemia
Trauma and Surgery
Cancer Treatment
Bleeding Disorders
Others (Others include rare blood diseases)
By End User
Hospitals
Ambulatory Surgical Centers
Blood and Blood Component Bank
Others
By Country/Region
South Africa
Central Africa
North Africa
Company Profiles
Becton, Dickinson & Co.*
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Kidde-Fenwal Inc.
Bio-Rad Laboratories, Inc.
Cerus Corporation
Immucor
Beckman Coulter, Inc.
bioMérieux SA
Octapharma AG
Abbott
CSL Behring LLC
MacoPharma
Shanghai RAAS
China Biologic Products Holdings, Inc.
Takeda Pharmaceutical Company Limited
Grifols S.A.
Bharat Serums and Vaccines Ltd.
Terumo BCT Inc.
“*” marked represents similar segmentation in other categories in the respective section.